{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T13:40:39Z","timestamp":1707831639894},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1007\/s11899-007-0004-4","type":"journal-article","created":{"date-parts":[[2007,4,18]],"date-time":"2007-04-18T14:29:54Z","timestamp":1176906594000},"page":"25-33","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia"],"prefix":"10.1007","volume":"2","author":[{"given":"Ruben A.","family":"Mesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,4,15]]},"reference":[{"key":"4_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","volume":"342","author":"A. Tefferi","year":"2000","unstructured":"Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 2000, 342:1255\u20131265.","journal-title":"N Engl J Med"},{"key":"4_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","volume":"61","author":"R.A. Mesa","year":"1999","unstructured":"Mesa RA, Silverstein MN, Jacobsen SJ, et al.: Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976\u20131995. Am J Hematol 1999, 61:10\u201315.","journal-title":"Am J Hematol"},{"key":"4_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1034\/j.1600-0609.2001.066005324.x","volume":"66","author":"F. Cervantes","year":"2001","unstructured":"Cervantes F, Barosi G, Hernandez-Boluda JC, et al.: Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. Eur J Haematol 2001, 66:324\u2013327.","journal-title":"Eur J Haematol"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","volume":"95","author":"A. Tefferi","year":"2000","unstructured":"Tefferi A, Mesa RA, Nagorney DM, et al.: Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000, 95:2226\u20132233.","journal-title":"Blood"},{"key":"4_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4065\/78.10.1223","volume":"78","author":"C.A. Koch","year":"2003","unstructured":"Koch CA, Li CY, Mesa RA, Tefferi A: Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003, 78:1223\u20131233.","journal-title":"Mayo Clin Proc"},{"key":"4_CR6","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1182\/blood.V97.11.3665","volume":"97","author":"R.A. Mesa","year":"2001","unstructured":"Mesa RA, Li CY, Schroeder G, Tefferi A: Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood 2001, 97:3665\u20133667.","journal-title":"Blood"},{"key":"4_CR7","doi-asserted-by":"crossref","unstructured":"Mesa RA, Wadleigh M, Niblack J, et al.: Fatigue, the un-addressed curse of myeloproliferative diseases (MPD): results of an international Internet based QOL survey of 830 MPD patients [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 2577.","DOI":"10.1182\/blood.V106.11.2577.2577"},{"key":"4_CR8","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","volume":"102","author":"H.J. Deeg","year":"2003","unstructured":"Deeg HJ, Gooley TA, Flowers ME, et al.: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003, 102:3912\u20133918.","journal-title":"Blood"},{"key":"4_CR9","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","volume":"105","author":"D. Rondelli","year":"2005","unstructured":"Rondelli D, Barosi G, Bacigalupo A, et al.: Allogeneic hematopoietic stem-cell transplantation with reduced intensity conditioning in intermediate-or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 105:4115\u20134119.","journal-title":"Blood"},{"key":"4_CR10","first-page":"616","volume":"83","author":"J.N. Rodriguez","year":"1998","unstructured":"Rodriguez JN, Martino ML, Dieguez JC, Prados D: rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 1998, 83:616\u2013621.","journal-title":"Haematologica"},{"key":"4_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","volume":"127","author":"F. Cervantes","year":"2004","unstructured":"Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al.: Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004, 127:399\u2013403.","journal-title":"Br J Haematol"},{"key":"4_CR12","first-page":"595","volume":"85","author":"F. Cervantes","year":"2000","unstructured":"Cervantes F, Hernandez-Boluda JC, Alvarez A, et al.: Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000, 85:595\u2013599.","journal-title":"Haematologica"},{"key":"4_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1365-2141.2001.02918.x","volume":"114","author":"G. Barosi","year":"2001","unstructured":"Barosi G, Grossi A, Comotti B, et al.: Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001, 114:78\u201383.","journal-title":"Br J Haematol"},{"key":"4_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","volume":"22","author":"M. Marchetti","year":"2004","unstructured":"Marchetti M, Barosi G, Balestri F, et al.: Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004, 22:424\u2013431.","journal-title":"J Clin Oncol"},{"key":"4_CR15","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","volume":"101","author":"R.A. Mesa","year":"2003","unstructured":"Mesa RA, Steensma DP, Pardanani A, et al.: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003, 101:2534\u20132541.","journal-title":"Blood"},{"key":"4_CR16","doi-asserted-by":"crossref","unstructured":"Mesa RA, Stensma DP, Li CY, et al.: Phase II study of the combination of low-dose thalidomide, prednisone, and etanercept (PET regimen) in the treatment of anemia, splenomegaly, and constitutional symptoms associated with myelofibrosis with myeloid metaplasia (MMM) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 2576.","DOI":"10.1182\/blood.V106.11.2576.2576"},{"key":"4_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-0609.2004.00386.x","volume":"74","author":"L. Benetatos","year":"2005","unstructured":"Benetatos L, Chaidos A, Alymara V, et al.: Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis. Eur J Haematol 2005, 74:273\u2013274.","journal-title":"Eur J Haematol"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.4049\/jimmunol.154.11.6040","volume":"154","author":"E.J. Battegay","year":"1995","unstructured":"Battegay EJ, Raines EW, Colbert T, Ross R: TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J Immunol 1995, 154:6040\u20136047.","journal-title":"J Immunol"},{"key":"4_CR19","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1182\/blood.V99.6.2252","volume":"99","author":"D.P. Steensma","year":"2002","unstructured":"Steensma DP, Mesa RA, Li CY, et al.: Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 2002, 99:2252\u20132254.","journal-title":"Blood"},{"key":"4_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1600-0609.1988.tb00212.x","volume":"41","author":"E. Lofvenberg","year":"1988","unstructured":"Lofvenberg E, Wahlin A: Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988, 41:375\u2013381.","journal-title":"Eur J Haematol"},{"key":"4_CR21","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","volume":"116","author":"M.C. Petti","year":"2002","unstructured":"Petti MC, Latagliata R, Spadea T, et al.: Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002, 116:576\u2013581.","journal-title":"Br J Haematol"},{"key":"4_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1600-0609.2004.00370.x","volume":"74","author":"L.N. Faoro","year":"2005","unstructured":"Faoro LN, Tefferi A, Mesa RA: Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005, 74:117\u2013120.","journal-title":"Eur J Haematol"},{"key":"4_CR23","unstructured":"Huang J, Xu J: Proliferation of human marrow fibroblasts suppressed synergistically by interferon alpha and TGF-\u03b21 in vitro [abstract]. Blood (ASH Annual Meeting Abstracts) 2003, 102:Abstract 5077."},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V70.4.1014.1014","volume":"70","author":"C. Carlo-Stella","year":"1987","unstructured":"Carlo-Stella C, Cazzola M, Gasner A, et al.: Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 1987, 70:1014\u20131019.","journal-title":"Blood"},{"key":"4_CR25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2141.1994.tb04802.x","volume":"86","author":"K.P. Dalla","year":"1994","unstructured":"Dalla KP, Zeigler ZR, Shadduck RK: Alpha-interferon in myelofibrosis: a case report [see comments]. Br J Haematol 1994, 86:654\u2013656.","journal-title":"Br J Haematol"},{"key":"4_CR26","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood.V97.6.1896","volume":"97","author":"A. Tefferi","year":"2001","unstructured":"Tefferi A, Elliot MA, Yoon SY, et al.: Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia [letter]. Blood 2001, 97:1896.","journal-title":"Blood"},{"key":"4_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s002770000231","volume":"80","author":"N. Heis-Vahidi-Fard","year":"2001","unstructured":"Heis-Vahidi-Fard N, Forberg E, Eichinger S, et al.: Ineffectiveness of interferon-gamma in the treatment of idiopathic myelofibrosis: a pilot study. Ann Hematol 2001, 80:79\u201382.","journal-title":"Ann Hematol"},{"key":"4_CR28","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Lawhorn, K, Giles F, et al.: PEG-Intron for myeloproliferative diseases: an update of ongoing phase II study [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 633.","DOI":"10.1182\/blood.V104.11.1517.1517"},{"key":"4_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","volume":"105","author":"R.A. Mesa","year":"2005","unstructured":"Mesa RA, Li CY, Ketterling RP, et al.: Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005, 105:973\u2013977.","journal-title":"Blood"},{"key":"4_CR30","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C. James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144\u20131148.","journal-title":"Nature"},{"key":"4_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","volume":"131","author":"A. Tefferi","year":"2005","unstructured":"Tefferi A, Lasho TL, Schwager SM, et al.: The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005, 131:320\u2013328.","journal-title":"Br J Haematol"},{"key":"4_CR32","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1182\/blood-2004-06-2485","volume":"105","author":"M. Xu","year":"2005","unstructured":"Xu M, Bruno E, Chao J, et al.: The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood 2005, 105:1699\u20131705.","journal-title":"Blood"},{"key":"4_CR33","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","volume":"108","author":"A. Tefferi","year":"2006","unstructured":"Tefferi A, Cortes J, Verstovsek S, et al.: Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006, 108:1158\u20131164.","journal-title":"Blood"},{"key":"4_CR34","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","volume":"9","author":"G.W. Muller","year":"1999","unstructured":"Muller GW, Chen R, Huang SY, et al.: Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999, 9:1625\u20131630.","journal-title":"Bioorg Med Chem Lett"},{"key":"4_CR35","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","volume":"101","author":"A.M. O\u2019Farrell","year":"2003","unstructured":"O\u2019Farrell AM, Abrams TJ, Yuen HA, et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597\u20133605.","journal-title":"Blood"},{"key":"4_CR36","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","volume":"105","author":"W. Fiedler","year":"2005","unstructured":"Fiedler W, Serve H, Dohner H, et al.: A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005, 105:986\u2013993.","journal-title":"Blood"},{"key":"4_CR37","first-page":"2178","volume":"60","author":"J.M. Wood","year":"2000","unstructured":"Wood JM, Bold G, Buchdunger E, et al.: PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 60:2178\u20132189.","journal-title":"Cancer Res"},{"key":"4_CR38","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/cncr.11315","volume":"97","author":"F.J. Giles","year":"2003","unstructured":"Giles FJ, Cooper MA, Silverman L, et al.: Phase II study of SU5416\u2014a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor\u2014in patients with refractory myeloproliferative diseases. Cancer 2003, 97:1920\u20131928.","journal-title":"Cancer"},{"key":"4_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0306-9877(03)00155-5","volume":"61","author":"H. Hasselbach","year":"2003","unstructured":"Hasselbach H: SU6668 in idiopathic myelofibrosis\u2014a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis. Med Hypotheses 2003, 61:244\u2013247.","journal-title":"Med Hypotheses"},{"key":"4_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H. Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645\u2013652.","journal-title":"N Engl J Med"},{"key":"4_CR41","first-page":"1245","volume":"19","author":"H.M. Kvasnicka","year":"2004","unstructured":"Kvasnicka HM, Thiele J: Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol 2004, 19:1245\u20131260.","journal-title":"Histol Histopathol"},{"key":"4_CR42","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1182\/blood-2001-12-0154","volume":"99","author":"A. Tefferi","year":"2002","unstructured":"Tefferi A, Mesa RA, Gray LA, et al.: Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 2002, 99:3854\u20133856.","journal-title":"Blood"},{"key":"4_CR43","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","volume":"101","author":"J. Cortes","year":"2003","unstructured":"Cortes J, Ault P, Koller C, et al.: Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003, 101:4714\u20134716.","journal-title":"Blood"},{"key":"4_CR44","doi-asserted-by":"crossref","unstructured":"LeBousse-Kerdil\u00e8s MC, Desterke C, Guerton B, et al.: Glivec\/STI571 treatment stimulates megakaryopoiesis and normalizes PDGF receptor beta kinase expression in thrombocytopenic patients with myeloid metaplasia with myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 2599.","DOI":"10.1182\/blood.V106.11.2599.2599"},{"key":"4_CR45","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"L.J. Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, et al.: Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658\u20136661.","journal-title":"J Med Chem"},{"key":"4_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2141.1994.tb04969.x","volume":"88","author":"J.T. Reilly","year":"1994","unstructured":"Reilly JT: Pathogenesis of idiopathic myelofibrosis: present status and future directions [review]. Br J Haematol 1994, 88:1\u20138.","journal-title":"Br J Haematol"},{"key":"4_CR47","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1999.17.3.1071","volume":"17","author":"D.M. Beaupre","year":"1999","unstructured":"Beaupre DM, Kurzrock R: RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 1999, 17:1071\u20131079.","journal-title":"J Clin Oncol"},{"key":"4_CR48","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/MCB.19.3.1831","volume":"19","author":"W. Du","year":"1999","unstructured":"Du W, Lebowitz PF, Prendergast GC: Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 1999, 19:1831\u20131840.","journal-title":"Mol Cell Biol"},{"key":"4_CR49","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2002-07-1973","volume":"101","author":"J. Cortes","year":"2003","unstructured":"Cortes J, Albitar M, Thomas D, et al.: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003, 101:1692\u20131697.","journal-title":"Blood"},{"key":"4_CR50","doi-asserted-by":"crossref","unstructured":"Mesa RA, Camoriano JK, Geyer SM, et al.: A Phase 2 Consortium (P2C) trial of R115777 (tipifarnib) in myelofibrosis with myeloid metaplasia [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 1509.","DOI":"10.1182\/blood.V104.11.1509.1509"},{"key":"4_CR51","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/nrd1580","volume":"3","author":"J.M. Yingling","year":"2004","unstructured":"Yingling JM, Blanchard KL, Sawyer JS: Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004, 3:1011\u20131022.","journal-title":"Nat Rev Drug Discov"},{"key":"4_CR52","doi-asserted-by":"crossref","unstructured":"Schlingensiepen K, Bischof A, Egger T, et al.: The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies [abstract]. Proc Am Soc Clin Oncol 2004, 23:Abstract 3132.","DOI":"10.1200\/jco.2004.22.90140.3132"},{"key":"4_CR53","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1016\/j.bmcl.2004.04.007","volume":"14","author":"J.S. Sawyer","year":"2004","unstructured":"Sawyer JS, Beight DW, Britt KS, et al.: Synthesis and activity of new aryl-and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett 2004, 14:3581\u20133584.","journal-title":"Bioorg Med Chem Lett"},{"key":"4_CR54","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1021\/jm0400247","volume":"47","author":"F. Gellibert","year":"2004","unstructured":"Gellibert F, Woolven J, Fouchet MH, et al.: Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem 2004, 47:4494\u20134506.","journal-title":"J Med Chem"},{"key":"4_CR55","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1021\/jm010493y","volume":"45","author":"J.F. Callahan","year":"2002","unstructured":"Callahan JF, Burgess JL, Fornwald JA, et al.: Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem 2002, 45:999\u20131001.","journal-title":"J Med Chem"},{"key":"4_CR56","doi-asserted-by":"publisher","first-page":"7954","DOI":"10.1158\/0008-5472.CAN-04-1013","volume":"64","author":"M. Uhl","year":"2004","unstructured":"Uhl M, Aulwurm S, Wischhusen J, et al.: SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004, 64:7954\u20137961.","journal-title":"Cancer Res"},{"key":"4_CR57","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2141.2001.02883.x","volume":"114","author":"R.A. Mesa","year":"2001","unstructured":"Mesa RA, Tefferi A, Elliott MA, et al.: A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol 2001, 114:111\u2013113.","journal-title":"Br J Haematol"},{"key":"4_CR58","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S, Kipps TJ, Faderl S, et al.: A phase I trial of the small molecule pan-Bcl-2 family inhibitor GX15-070 administered intravenously (IV) every 3 weeks to patients with previously treated chronic lymphocytic leukemia (CLL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 446.","DOI":"10.1182\/blood.V106.11.446.446"},{"key":"4_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0065-230X(08)60702-2","volume":"72","author":"S.B. Baylin","year":"1998","unstructured":"Baylin SB, Herman JG, Graff JR, et al.: Alterations in DNA methylation: a fundamental aspect of neoplasia [review]. Adv Cancer Res 1998, 72:141\u2013196.","journal-title":"Adv Cancer Res"},{"key":"4_CR60","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1182\/blood-2002-11-3366","volume":"101","author":"M.C. Martyr\u00e9","year":"2003","unstructured":"Martyr\u00e9 MC, Steunou V, LeBousse-Kerdil\u00e8s MC, Wietzerbin J: Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis [letter]. Blood 2003, 101:5087\u20135088; response 5088\u20135089.","journal-title":"Blood"},{"key":"4_CR61","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","volume":"23","author":"J.P. Issa","year":"2005","unstructured":"Issa JP, Gharibyan V, Cortes J, et al.: Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005, 23:3948\u20133956.","journal-title":"J Clin Oncol"},{"key":"4_CR62","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1158\/0008-5472.CAN-04-2339","volume":"65","author":"E. Komura","year":"2005","unstructured":"Komura E, Tonetti C, Penard-Lacronique V, et al.: Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res 2005, 65:3281\u20133289.","journal-title":"Cancer Res"},{"key":"4_CR63","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.4049\/jimmunol.165.4.2271","volume":"165","author":"P. Rameshwar","year":"2000","unstructured":"Rameshwar P, Narayanan R, Qian J, et al.: NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000, 165:2271\u20132277.","journal-title":"J Immunol"},{"key":"4_CR64","doi-asserted-by":"crossref","unstructured":"Wagner-Ballon O, Gastinne T, Tulliez M, et al.: Proteasome inhibitor bortezomib can inhibit bone marrow fibrosis development in a murine model of myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 2582.","DOI":"10.1182\/blood.V106.11.2582.2582"},{"key":"4_CR65","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2141.1990.tb02609.x","volume":"75","author":"G. Visani","year":"1990","unstructured":"Visani G, Finelli C, Castelli U, et al.: Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990, 75:4\u20139.","journal-title":"Br J Haematol"},{"key":"4_CR66","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1046\/j.1365-2141.1998.00833.x","volume":"102","author":"F. Cervantes","year":"1998","unstructured":"Cervantes F, Barosi G, Demory JL, et al.: Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998, 102:684\u2013690.","journal-title":"Br J Haematol"},{"key":"4_CR67","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","volume":"88","author":"B. Dupriez","year":"1996","unstructured":"Dupriez B, Morel P, Demory JL, et al.: Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88:1013\u20131018.","journal-title":"Blood"},{"key":"4_CR68","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/cncr.21644","volume":"106","author":"D. Dingli","year":"2006","unstructured":"Dingli D, Schwager SM, Mesa RA, et al.: Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 2006, 106:623\u2013630.","journal-title":"Cancer"},{"key":"4_CR69","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1080\/1042819021000040008","volume":"43","author":"B. Giovanni","year":"2002","unstructured":"Giovanni B, Michelle E, Letizia C, et al.: Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002, 43:2301\u20132307.","journal-title":"Leuk Lymphoma"},{"key":"4_CR70","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1600-0609.1988.tb00212.x","volume":"41","author":"E. Lofvenberg","year":"1988","unstructured":"Lofvenberg E, Wahlin A: Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988, 41:375\u2013381.","journal-title":"Eur J Haematol"},{"key":"4_CR71","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1600-0609.1984.tb00724.x","volume":"33","author":"A. Manoharan","year":"1984","unstructured":"Manoharan A, Pitney WR: Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol 1984, 33:453\u2013459.","journal-title":"Scand J Haematol"},{"key":"4_CR72","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","volume":"89","author":"Y. Najean","year":"1997","unstructured":"Najean Y, Rain JD: Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997, 89:2319\u20132327.","journal-title":"Blood"},{"key":"4_CR73","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1046\/j.1365-2141.1997.3843198.x","volume":"99","author":"A. Tefferi","year":"1997","unstructured":"Tefferi A, Silverstein MN, Li CY: 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 1997, 99:352\u2013357.","journal-title":"Br J Haematol"},{"key":"4_CR74","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1124\/jpet.102.048496","volume":"305","author":"P.H. Schafer","year":"2003","unstructured":"Schafer PH, Gandhi AK, Loveland MA, et al.: Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003, 305:1222\u20131232.","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR75","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2174\/138161206775201910","volume":"12","author":"A.R. Cardones","year":"2006","unstructured":"Cardones AR, Banez LL: VEGF inhibitors in cancer therapy. Curr Pharm Des 2006, 12:387\u2013394.","journal-title":"Curr Pharm Des"},{"key":"4_CR76","doi-asserted-by":"crossref","unstructured":"Issa JP, Kantarjian H: Azacitidine. Nat Rev Drug Discov 2005, Suppl:S6\u2013S7.","DOI":"10.1038\/nrd1726"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0004-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-007-0004-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0004-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0004-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T13:23:22Z","timestamp":1707830602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-007-0004-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s11899-007-0004-4","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"15 April 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}